FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung Cancer with EGFR Exon 19 Deletions or L858R Mutations By Ogkologos - October 29, 2024 1687 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MARIPOSA-2 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Hospice Service Provides “Bucket List” Tattoo for 77-Year-Old Woman with Breast... June 11, 2019 Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients... December 9, 2024 New on NCI’s Websites, March 2020 March 16, 2020 ESMO Publishes First Guidance on the Safe Use of Large Language... October 18, 2025 Load more HOT NEWS Pattern of DNA Damage Links Colorectal Cancer and Diet High in... Snack Ideas and Tips for Better Sleep New insights on self-sampling for cervical cancer screening “I feel extremely proud when I look at what we’ve achieved”: ScottishPower’s Andrew...
